Editorial: Cancer Immunosurveillance
-
By
-
Sam Hanash
-
Luigi Buonaguro
-
Olivera Finn
-
June 12, 2026
-
Clinical Scorecard: Editorial: The Mechanisms of Immune Surveillance in Cancer
At a Glance
| Category | Detail |
|---|
| Condition | Cancer immunosurveillance |
| Key Mechanisms | Immune system elimination of tumors, immune evasion, T cell-mediated surveillance, and molecular mimicry. |
| Target Population | Individuals at risk for cancer, including those with hereditary syndromes. |
| Care Setting | Cancer prevention and immunotherapy. |
Key Highlights
- T cell-mediated immune surveillance can suppress tumor formation via NKG2D-NKG2DL interactions.
- SARS-CoV-2 antigens show homology to tumor-associated antigens, suggesting potential for cross-reactive T cell responses.
- HPV-specific humoral immunity kinetics are important for cervical cancer screening.
- Autoantibodies to specific antigens may serve as biomarkers for pancreatic ductal adenocarcinoma.
- Chronic stress can disrupt anti-tumor immunity and promote tumor progression.
Guideline-Based Recommendations
Diagnosis
- Comprehensive immune profiling at various disease stages is recommended.
Management
- Targeting stress signaling through pharmacological and behavioral interventions may improve immune surveillance.
Monitoring & Follow-up
- Monitoring humoral immune responses to tumor antigens can aid in diagnostic applications.
Risks
- Individuals with inherited susceptibility or other risk factors are at increased risk for cancer.
Patient & Prescribing Data
Women undergoing cervical cancer screening and individuals with hereditary cancer syndromes.
Vaccines targeting tumor-associated antigens may enhance cancer immunosurveillance.
Clinical Best Practices
- Utilize vaccines to strengthen cancer immunosurveillance in at-risk individuals.
- Assess pre-vaccination immune profiles to predict responses to cancer vaccines.
Related Resources & Content
